|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
infusion
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:cutaneous_squamous_cell_carcinoma
gptkb:urothelial_carcinoma
gptkb:cancer
gptkb:FDA
gptkb:head_and_neck_squamous_cell_carcinoma
gptkb:classical_Hodgkin_lymphoma
gptkb:microsatellite_instability-high_cancer
gptkb:primary_mediastinal_large_B-cell_lymphoma
gptkb:triple-negative_breast_cancer
2014
colorectal cancer
esophageal cancer
melanoma
hepatocellular carcinoma
gastric cancer
renal cell carcinoma
|
|
gptkbp:ATCCode
|
L01XC18
|
|
gptkbp:biosimilar
|
no
|
|
gptkbp:CASNumber
|
1374853-91-4
|
|
gptkbp:cost
|
expensive
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:pembrolizumab
|
|
gptkbp:halfLife
|
22 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Keytruda
|
|
gptkbp:indication
|
immunotherapy
|
|
gptkbp:KEGGID
|
D10568
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:China
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
PD-1 inhibitor
|
|
gptkbp:MedlinePlusID
|
a615040
|
|
gptkbp:patentExpired
|
2028 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescribes
|
advanced cancers
|
|
gptkbp:PubChem_CID
|
CHEMBL3185146
DB09037
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
constipation
fatigue
joint pain
cough
itching
rash
decreased appetite
immune-mediated adverse reactions
|
|
gptkbp:target
|
gptkb:programmed_cell_death_protein_1_(PD-1)
|
|
gptkbp:UNII
|
4Z3D8G7ULM
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|